Cargando…

The neutrophil elastase inhibitor, sivelestat, attenuates acute lung injury in patients with cardiopulmonary bypass

BACKGROUND: The sivelestat is a neutrophil elastase inhibitor thought to have an effect against acute lung injury (ALI) in patients after scheduled cardiac surgery. However, the beneficial effect of sivelestat in patients undergoing emergent cardiovascular surgery remains unclear. We aim to evaluate...

Descripción completa

Detalles Bibliográficos
Autores principales: Pan, Tuo, Tuoerxun, Tayierjiang, Chen, Xi, Yang, Cheng-Jin, Jiang, Chen-Yu, Zhu, Yi-Fan, Li, Ze-Shi, Jiang, Xin-Yi, Zhang, Hai-Tao, Zhang, He, Wang, Ya-Peng, Chen, Wei, Lu, Li-Chong, Ge, Min, Cheng, Yong-Qing, Wang, Dong-Jin, Zhou, Qing
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Frontiers Media S.A. 2023
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9902923/
https://www.ncbi.nlm.nih.gov/pubmed/36761773
http://dx.doi.org/10.3389/fimmu.2023.1082830
_version_ 1784883364281450496
author Pan, Tuo
Tuoerxun, Tayierjiang
Chen, Xi
Yang, Cheng-Jin
Jiang, Chen-Yu
Zhu, Yi-Fan
Li, Ze-Shi
Jiang, Xin-Yi
Zhang, Hai-Tao
Zhang, He
Wang, Ya-Peng
Chen, Wei
Lu, Li-Chong
Ge, Min
Cheng, Yong-Qing
Wang, Dong-Jin
Zhou, Qing
author_facet Pan, Tuo
Tuoerxun, Tayierjiang
Chen, Xi
Yang, Cheng-Jin
Jiang, Chen-Yu
Zhu, Yi-Fan
Li, Ze-Shi
Jiang, Xin-Yi
Zhang, Hai-Tao
Zhang, He
Wang, Ya-Peng
Chen, Wei
Lu, Li-Chong
Ge, Min
Cheng, Yong-Qing
Wang, Dong-Jin
Zhou, Qing
author_sort Pan, Tuo
collection PubMed
description BACKGROUND: The sivelestat is a neutrophil elastase inhibitor thought to have an effect against acute lung injury (ALI) in patients after scheduled cardiac surgery. However, the beneficial effect of sivelestat in patients undergoing emergent cardiovascular surgery remains unclear. We aim to evaluate the effect of sivelestat on pulmonary protection in patients with ALI after emergent cardiovascular surgery. METHODS: Firstly, a case-control study in 665 patients undergoing emergent cardiovascular surgery from January 1(st), 2020 to October 26(th), 2022 was performed. 52 patients who received sivelestat (0.2mg/kg/h for 3 days) and 613 age- and sex-matched controls. Secondly, a propensity-score matched cohort (sivelestat vs control: 50 vs 50) was performed in these 665 patients. The primary outcome was a composite of adverse outcomes, including 30-day mortality, ECMO, continuous renal replacement therapy (CRRT) and IABP, etc. The secondary outcome included pneumonia, ventricular arrhythmias and mechanical ventilation time, etc. RESULTS: In propensity-matched patients, the 30-day mortality (16% vs 24%, P=0.32), stroke (2% vs 8%, P=0.17), ECMO(6% vs 10%, P=0.46), IABP(4% vs 8%, P=0.40) and CRRT(8% vs 20%, P=0.08) had no differences between sivelestat and control group; sivelestat could significantly decrease pneumonia (40% vs 62%, P=0.03), mechanical ventilation time (median: 96hours, IQR:72-120hours vs median:148hours, IQR:110-186hours, P<0.01), bilateral pulmonary infiltrates (P<0.01), oxygen index (P<0.01), interleukin-6(P=0.02), procalcitonin(P<0.01) and C-reactive protein(P<0.01). CONCLUSION: Administration of sivelestat might improve postoperative outcomes in patients with ALI after emergent cardiovascular surgery. Our results show that sivelestat may be considered to protect pulmonary function against inflammatory injury by CPB. REGISTRATION: http://www.chictr.org.cn/showproj.aspx?proj=166643, identifier ChiCTR2200059102.
format Online
Article
Text
id pubmed-9902923
institution National Center for Biotechnology Information
language English
publishDate 2023
publisher Frontiers Media S.A.
record_format MEDLINE/PubMed
spelling pubmed-99029232023-02-08 The neutrophil elastase inhibitor, sivelestat, attenuates acute lung injury in patients with cardiopulmonary bypass Pan, Tuo Tuoerxun, Tayierjiang Chen, Xi Yang, Cheng-Jin Jiang, Chen-Yu Zhu, Yi-Fan Li, Ze-Shi Jiang, Xin-Yi Zhang, Hai-Tao Zhang, He Wang, Ya-Peng Chen, Wei Lu, Li-Chong Ge, Min Cheng, Yong-Qing Wang, Dong-Jin Zhou, Qing Front Immunol Immunology BACKGROUND: The sivelestat is a neutrophil elastase inhibitor thought to have an effect against acute lung injury (ALI) in patients after scheduled cardiac surgery. However, the beneficial effect of sivelestat in patients undergoing emergent cardiovascular surgery remains unclear. We aim to evaluate the effect of sivelestat on pulmonary protection in patients with ALI after emergent cardiovascular surgery. METHODS: Firstly, a case-control study in 665 patients undergoing emergent cardiovascular surgery from January 1(st), 2020 to October 26(th), 2022 was performed. 52 patients who received sivelestat (0.2mg/kg/h for 3 days) and 613 age- and sex-matched controls. Secondly, a propensity-score matched cohort (sivelestat vs control: 50 vs 50) was performed in these 665 patients. The primary outcome was a composite of adverse outcomes, including 30-day mortality, ECMO, continuous renal replacement therapy (CRRT) and IABP, etc. The secondary outcome included pneumonia, ventricular arrhythmias and mechanical ventilation time, etc. RESULTS: In propensity-matched patients, the 30-day mortality (16% vs 24%, P=0.32), stroke (2% vs 8%, P=0.17), ECMO(6% vs 10%, P=0.46), IABP(4% vs 8%, P=0.40) and CRRT(8% vs 20%, P=0.08) had no differences between sivelestat and control group; sivelestat could significantly decrease pneumonia (40% vs 62%, P=0.03), mechanical ventilation time (median: 96hours, IQR:72-120hours vs median:148hours, IQR:110-186hours, P<0.01), bilateral pulmonary infiltrates (P<0.01), oxygen index (P<0.01), interleukin-6(P=0.02), procalcitonin(P<0.01) and C-reactive protein(P<0.01). CONCLUSION: Administration of sivelestat might improve postoperative outcomes in patients with ALI after emergent cardiovascular surgery. Our results show that sivelestat may be considered to protect pulmonary function against inflammatory injury by CPB. REGISTRATION: http://www.chictr.org.cn/showproj.aspx?proj=166643, identifier ChiCTR2200059102. Frontiers Media S.A. 2023-01-24 /pmc/articles/PMC9902923/ /pubmed/36761773 http://dx.doi.org/10.3389/fimmu.2023.1082830 Text en Copyright © 2023 Pan, Tuoerxun, Chen, Yang, Jiang, Zhu, Li, Jiang, Zhang, Zhang, Wang, Chen, Lu, Ge, Cheng, Wang and Zhou https://creativecommons.org/licenses/by/4.0/This is an open-access article distributed under the terms of the Creative Commons Attribution License (CC BY). The use, distribution or reproduction in other forums is permitted, provided the original author(s) and the copyright owner(s) are credited and that the original publication in this journal is cited, in accordance with accepted academic practice. No use, distribution or reproduction is permitted which does not comply with these terms.
spellingShingle Immunology
Pan, Tuo
Tuoerxun, Tayierjiang
Chen, Xi
Yang, Cheng-Jin
Jiang, Chen-Yu
Zhu, Yi-Fan
Li, Ze-Shi
Jiang, Xin-Yi
Zhang, Hai-Tao
Zhang, He
Wang, Ya-Peng
Chen, Wei
Lu, Li-Chong
Ge, Min
Cheng, Yong-Qing
Wang, Dong-Jin
Zhou, Qing
The neutrophil elastase inhibitor, sivelestat, attenuates acute lung injury in patients with cardiopulmonary bypass
title The neutrophil elastase inhibitor, sivelestat, attenuates acute lung injury in patients with cardiopulmonary bypass
title_full The neutrophil elastase inhibitor, sivelestat, attenuates acute lung injury in patients with cardiopulmonary bypass
title_fullStr The neutrophil elastase inhibitor, sivelestat, attenuates acute lung injury in patients with cardiopulmonary bypass
title_full_unstemmed The neutrophil elastase inhibitor, sivelestat, attenuates acute lung injury in patients with cardiopulmonary bypass
title_short The neutrophil elastase inhibitor, sivelestat, attenuates acute lung injury in patients with cardiopulmonary bypass
title_sort neutrophil elastase inhibitor, sivelestat, attenuates acute lung injury in patients with cardiopulmonary bypass
topic Immunology
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9902923/
https://www.ncbi.nlm.nih.gov/pubmed/36761773
http://dx.doi.org/10.3389/fimmu.2023.1082830
work_keys_str_mv AT pantuo theneutrophilelastaseinhibitorsivelestatattenuatesacutelunginjuryinpatientswithcardiopulmonarybypass
AT tuoerxuntayierjiang theneutrophilelastaseinhibitorsivelestatattenuatesacutelunginjuryinpatientswithcardiopulmonarybypass
AT chenxi theneutrophilelastaseinhibitorsivelestatattenuatesacutelunginjuryinpatientswithcardiopulmonarybypass
AT yangchengjin theneutrophilelastaseinhibitorsivelestatattenuatesacutelunginjuryinpatientswithcardiopulmonarybypass
AT jiangchenyu theneutrophilelastaseinhibitorsivelestatattenuatesacutelunginjuryinpatientswithcardiopulmonarybypass
AT zhuyifan theneutrophilelastaseinhibitorsivelestatattenuatesacutelunginjuryinpatientswithcardiopulmonarybypass
AT lizeshi theneutrophilelastaseinhibitorsivelestatattenuatesacutelunginjuryinpatientswithcardiopulmonarybypass
AT jiangxinyi theneutrophilelastaseinhibitorsivelestatattenuatesacutelunginjuryinpatientswithcardiopulmonarybypass
AT zhanghaitao theneutrophilelastaseinhibitorsivelestatattenuatesacutelunginjuryinpatientswithcardiopulmonarybypass
AT zhanghe theneutrophilelastaseinhibitorsivelestatattenuatesacutelunginjuryinpatientswithcardiopulmonarybypass
AT wangyapeng theneutrophilelastaseinhibitorsivelestatattenuatesacutelunginjuryinpatientswithcardiopulmonarybypass
AT chenwei theneutrophilelastaseinhibitorsivelestatattenuatesacutelunginjuryinpatientswithcardiopulmonarybypass
AT lulichong theneutrophilelastaseinhibitorsivelestatattenuatesacutelunginjuryinpatientswithcardiopulmonarybypass
AT gemin theneutrophilelastaseinhibitorsivelestatattenuatesacutelunginjuryinpatientswithcardiopulmonarybypass
AT chengyongqing theneutrophilelastaseinhibitorsivelestatattenuatesacutelunginjuryinpatientswithcardiopulmonarybypass
AT wangdongjin theneutrophilelastaseinhibitorsivelestatattenuatesacutelunginjuryinpatientswithcardiopulmonarybypass
AT zhouqing theneutrophilelastaseinhibitorsivelestatattenuatesacutelunginjuryinpatientswithcardiopulmonarybypass
AT pantuo neutrophilelastaseinhibitorsivelestatattenuatesacutelunginjuryinpatientswithcardiopulmonarybypass
AT tuoerxuntayierjiang neutrophilelastaseinhibitorsivelestatattenuatesacutelunginjuryinpatientswithcardiopulmonarybypass
AT chenxi neutrophilelastaseinhibitorsivelestatattenuatesacutelunginjuryinpatientswithcardiopulmonarybypass
AT yangchengjin neutrophilelastaseinhibitorsivelestatattenuatesacutelunginjuryinpatientswithcardiopulmonarybypass
AT jiangchenyu neutrophilelastaseinhibitorsivelestatattenuatesacutelunginjuryinpatientswithcardiopulmonarybypass
AT zhuyifan neutrophilelastaseinhibitorsivelestatattenuatesacutelunginjuryinpatientswithcardiopulmonarybypass
AT lizeshi neutrophilelastaseinhibitorsivelestatattenuatesacutelunginjuryinpatientswithcardiopulmonarybypass
AT jiangxinyi neutrophilelastaseinhibitorsivelestatattenuatesacutelunginjuryinpatientswithcardiopulmonarybypass
AT zhanghaitao neutrophilelastaseinhibitorsivelestatattenuatesacutelunginjuryinpatientswithcardiopulmonarybypass
AT zhanghe neutrophilelastaseinhibitorsivelestatattenuatesacutelunginjuryinpatientswithcardiopulmonarybypass
AT wangyapeng neutrophilelastaseinhibitorsivelestatattenuatesacutelunginjuryinpatientswithcardiopulmonarybypass
AT chenwei neutrophilelastaseinhibitorsivelestatattenuatesacutelunginjuryinpatientswithcardiopulmonarybypass
AT lulichong neutrophilelastaseinhibitorsivelestatattenuatesacutelunginjuryinpatientswithcardiopulmonarybypass
AT gemin neutrophilelastaseinhibitorsivelestatattenuatesacutelunginjuryinpatientswithcardiopulmonarybypass
AT chengyongqing neutrophilelastaseinhibitorsivelestatattenuatesacutelunginjuryinpatientswithcardiopulmonarybypass
AT wangdongjin neutrophilelastaseinhibitorsivelestatattenuatesacutelunginjuryinpatientswithcardiopulmonarybypass
AT zhouqing neutrophilelastaseinhibitorsivelestatattenuatesacutelunginjuryinpatientswithcardiopulmonarybypass